Vermillion Inks CRADA with Army to Evaluate OVA1 | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion has signed a cooperative research and development agreement, or CRADA, with the US Army Medical Research and Materiel Command for the evaluation of the OVA1 ovarian cancer diagnostic test, Vermillion announced today.

The project, which follows a decision by the Army to cover the OVA1 test in January 2012, will be carried out in two phases to assess the cost-benefit profile of Vermillion's test as a presurgical standard of care in women with pelvic masses and to evaluate OVA1's clinical utility in a managed care setting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.